Education:

Ph.D, Urology, Tianjin Medical University, Tianjin, China, 2007

M.S, Urology, Xuzhou Medical College, Xuzhou, China, 1998

M.D, Clinical Medicine, Xuzhou Medical College, Xuzhou, China, 1989

Post and Present Positions:

2018-present, President of Xuzhou Medical University, Xuzhou, China

2014-2018, Vice-Chancellor of Xuzhou Medical University, Xuzhou, China

2010-present, Director of Institute of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, China

2006-2014, Vice president of the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China

2006-present, Chief Physician, Dean of Oncology Department of Affiliated Hospital of Xuzhou Medical University, Xuzhou, China

1998-present, Assistant (1998-2001), Associate (2001-2005) and Professor (2005-present) of Urology, Xuzhou Medical University, Xuzhou, China

1989-1995, Residency in the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China

Research Interests:

Dr. Zheng and his research team are aiming to develop innovative strategies to tumor biotherapy with CAR-T and oncolytic virus. Humanized dual-target CAR-T has been developed in his lab, which successfully overcomes current challenges in the treatment of recurrent or refractory hematologic malignancies. In addition, a new generation of oncolytic adenovirus has been developed to treat solid tumors solely, or help CAR-T cells to surmount immunosuppressive mechanisms within tumor microenvironment. Dr. Zheng is currently dedicated to the industrial development of these cancer biotherapy products.

Awards and Honors:

2021 Science and Technology Award (Second Class) by Chinese Medical Association

2019 Science and Technology Award (First Class) by Jiangsu Province, China

2015/2012 Natural Science Award (Second Class) by the Ministry of Education, China

2015/2010/2009/2008/2003 Science and Technology Award (Third Class) by Jiangsu Province, China

2010 Science and Technology Award (Third Class) by Chinese Medical Association

Professional Activities:

2019.10-2024.10, Director of China Medicinal Biotechnology Association (CMBA)

2021.06-2024.06, Deputy Director of the Biological Therapy Professional Committee of Jiangsu Research Hospital Association

2018.09-2022.08, member of Medical Biotechnology Clinical Application Committee of CMBA

2016.09-2021.09, Deputy Director of Jiangsu Health Standardization Technical Committee

2016.06-2021.05, Executive Director of the Tenth Council of Jiangsu Medical Association (JMA)

2015.11-2020.10, Deputy Director of the Medical Science Research Branch of JMA

2015.01-2019.12, Invited Executive Director of Jiangsu Biotechnology Association

2014.09-2017.08, Vice Chairman of the Professional Committee of Hospital Science and Technology Education Management of Jiangsu Hospital Association

2014.01-2016.12, Deputy Head of the Oncology Group of the Urology Branch of JMA

Editorial Boards:

CHINESE JOURNAL OF EXPERIMENTAL SURGERY

Research Grants:

National R&D Key Program

Construction of integrated technical platform for developing novel oncolytic adenovirus products (2018YFA0900900). 2019-2024

NSFC

1. Therapeutic effects of Decorin-expressing oncolytic adenovirus in combination with CAIX-targeted CAR-T in treatment of renal cell carcinoma (81872488). 2019-2022

2. Therapeutic effects of Decorin-expressing, HER-controlled oncolytic adenovirus coupled with CPPs in treatment of renal cell carcinoma (81372460). 2014-2017

3. Anti-tumor effects of dual tumor-targeting, conditionally proliferative oncolytic adenovirus harboring de-ubiquitinated IL-24 and RGD peptide (81071854). 2011-2013

4. Screening of neoantigen and its application in cancer therapy (International Collaborative Project 81210108033) 2012-2013

5. Therapeutic effects of Ki-67 promoter-controlled, conditionally proliferative oncolytic adenovirus harboring dual-gene-targeted siRNAs (30972976). 2010-2012

6. Tumor-targeting vector carrying Ki67 siRNAs in renal carcinoma treatment (30570385) 2006-2008

7. Knockdown of Ki67 by siRNAs and shRNAs in human renal carcinoma cells and its application in cancer therapy (30370331) 2004

R&D key program of Jiangsu Province

1. Synergistic effect of CAIX-CAR-T and oncolytic adenovirus-carrying IFNγ+IL12+CCL5 in renal carcinoma treatment (BE2020641).2020-2023

2. Development of personalized CAIX-CAR-T cell therapy for renal cancer (BE2016643). 2016-2019

3. Standardization of autologous immune cell therapy for tumors (BL2012020). 2012-2015

Chinese Patents:

1. Deubiquitination mutant of mda-7/IL-24. Junnian Zheng, Dongsheng Pei, Junjie Liu, Baofu Zhang, Haiyan Xu, Liantao Li, Hui Tian. ZL201010244102.X

2. Chimeric antigen receptor hFVIIL-CD8-OX40-CD3zeta and application thereof. Junnian Zheng, Qing Zhang, Dongsheng Pei, Jie Yang, Liantao Li, Huizhong Li, Baofu Zhang, Lin Fang, Tiesuo Zhao, Qian Cheng, Longzhen Zhang. ZL201210375577.1

3. Preparation method of high-purity, high-multiplication capacity and high-cytotoxin activity CIK (cytokine induced kill) cell. Junnian Zheng, Liantao Li, Huizhong Li, Junjie Liu, Wei Xu, Feifei Chen, Qian Cheng, Longzhen Zhang, Dongsheng Pei. ZL201110036490.7

4. Novel cytokine-induced killer cells deliver dual-regulated oncolytic adenovirus which armed with cytokine. Junnian Zheng, Baofu Zhang, Junjie Liu, Liantao Li, Huizhong Li, Wei Xu, Dongsheng Pei. ZL201110020769.6

5. Ki67mRNA real-time fluorescence quantitative RT-PCR detection reagent kit. Junnian Zheng, Feng Gu, Dongsheng Pei, Ping Ma, Feifei Chen, Jiehui Di, Baofu Zhang, Wei Xu, Wang Li. ZL200910182571.0

6. Preparation and uses of Mda-7/IL-24 mutant polypeptide. Junnian Zheng, Dongsheng Pei, Baofu Zhang, Meilin Shi, Wang Li, Wei Xu, Junjie Liu. ZL200910024529.6

7. Human tumour specific Ki67 gene promotor. Junnian Zheng, Dongsheng Pei, Xiaoyun Liu, Fanghao Sun, Dong Han, Yuan Li, Wang Li. ZL200810022295.7

8. Preparation and uses of IL-18 mutant polypeptide. Junnian Zheng, Dongsheng Pei, Yafeng Sun, Yi Fu, Huiren Zhao, Liang Lu, Shuqun Hu, Hu Zhou. ZL200710022523.6

9. Invariant NKT cells co-expressing fully human B7H3-specific chimeric antigen receptor and IL-21 and its use thereof. Huizhong Li, Junnian Zheng, Gang Wang, Yilin Liu, Yuanyuan Dang. ZL202110783589.7

10. Chimeric Antigen Receptor (CAR) NK cells targeting B7H3. Huizhong Li, Junnian Zheng, Gang Wang, Peiyu Cao. ZL202110736533.6

11. Fully human Chimeric Antigen Receptor (CAR) T cells targeting CD276 and uses thereof. Gang Wang, Junnian Zheng, Huizhong Li, Peiyu Cao, Meng Wang. ZL202110768592.1

12. Chimeric antigen receptor against human CAIX antigen and application thereof. Qing Zhang, Junnian Zheng, Mengmeng Lu, Huizhong Li. ZL201910055339.4

13. Fully human scFv targeting CD276 and its usage in generating chimeric antigen receptor and engineered immune Cells. Gang Wang, Junnian Zheng, Bo Zhao, Huizhong Li, Peiyu Cao, Xinyu Li, Meng Wang, Xiaotong Kang, Yanan Wang. ZL202110739700.2

14. Novel fully human B7H3 antibody, incorporations and uses thereof. Gang Wang, Junnian Zheng, Bo Zhao, Xinyu Li, Xiaotong Kang, Yanan Wang. ZL202110736498.8

15. Application of PinX1 and its target molecule in preparing medicine for treating renal cell carcinoma. Jin Bai, Pingfu Hou, Junnian Zheng, Hailong Li, Hongmei Yong, Minle Li, Zhongwei Li. ZL201910541822.3

16. A drug targets for treatment of colon cancer. Pingfu Hou, Jin Bai, Junnian Zheng, Fang Chen, Minle Li, Zhongwei Li. ZL201910508815.3

17. Molecular marker for development of gastric cancer diagnostic products and application. Dong Dong, Junnian Zheng, Qiang Su. ZL202010499027.5

18. Four sgRNAs targeting human ADRB2 gene. Ming Shi, Junnian Zheng, Dan Liu, Yu Sun . ZL201810382911.3

19. Application of biomarker in cancer diagnosis. Dong Dong, Junnian Zheng, Qianqian Ning. ZL202010499576.2

20. Molecular marker for cancer diagnosis. Dong Dong, Junnian Zheng, Man Li. ZL202010499066.5

21. Biomarker related to occurrence and development of gastric adenocarcinoma. Dongdong, Junnian Zheng, Qianqian Ning, Man Li. ZL202010499024.1

22. Molecular marker and application thereof in cancer. Dong Dong, Junnian Zheng. ZL202010499021.8

23. Novel method to improve infection efficiency of the lentivirus carrying CAR (chimeric antigene receptor) genes in primary human T cells. Ming Shi, Yu Sun, Dan Liu, Anqun Tang, Junnian Zheng. ZL201811585239.4

24. Application of MCD gene and expression products in preparation of reagents for diagnosis and treatment of renal cancer staging or metastasis. Yong Liu, Xuefei Zhong, Min Yuan, Jin Bai, Junnian Zheng. ZL201910571884.9

25. The small molecule drug targeting zinc finger domain of MDM2 and its antitumor application. Yong Liu, Jian Gao, Jiehui Di, Bingwu Wang, Junnian Zheng. ZL201910552173.7

26. Spirooxindole-pyrroliziding derivatives and application thereof as tumor therapy medicine. Hong Yao, Junnian Zheng, Songlei Zhu, Jin Bai, Maomao Guo, Zhihong Liu.  ZL201511008077.4

Selected publications:

1. Zhang C, Fang L, Wang X, Yuan S, Li W, Tian W, Chen J, Zhang Q, Zhang Y, Zhang Q*, Zheng J*: Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma. Mol Ther Oncolytics 2022, 24:14-25.

2. Shi M, Li L, Wang S, Cheng H, Chen W, Sang W, Qi K, Li Z, Wang G, Li H, Lan J, Huang J, Fei X, Yu M, Li F, Qiao J, Wu Q, Zeng L, Jing G, Zheng J*, Gale RP, Xu K*, Cao J*: Safety and efficacy of a humanized CD19 chimeric antigen receptor T Cells for relapsed/refractory acute lymphoblastic leukaemia. American Journal of Hematology 2022.

3. Wu B, Zhang G, Guo Z, Wang G, Xu X, Li JL, Whitmire JK, Zheng J*, Wan YY*: The SKI proto-oncogene restrains the resident CD103(+)CD8(+) T cell response in viral clearance. Cell Mol Immunol 2021, 18(10):2410-2421.

4. Wang S, Wang X, Ye C, Cheng H, Shi M, Chen W, Qi K, Wang G, Wu Q, Zeng L, Li Z, Jing G, Zheng J*, Xu K*, Cao J*: Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia. Am J Hematol 2021, 96(5):E162-E165.

5. Qi K, Yan Z, Cheng H, Chen W, Wang Y, Wang X, Cao J, Zhang H, Sang W, Zhu F, Sun H, Li D, Wu Q, Qiao J, Fu C, Zeng L, Li Z, Zheng J*, Xu K*: An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study. Front Oncol 2021, 11:691064.

6. Ma B, Wells A, Wei L, Zheng J*. Prostate cancer liver metastasis: Dormancy and resistance to therapy. Semin Cancer Biol, 2021, 71: 2-9.

7. Liu D, Xu X, Dai Y, Zhao X, Bao S, Ma W, Zha L, Liu S, Liu Y, Zheng J*, Shi M*. Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment. Journal for immunotherapy of cancer 2021, 9(1)

8. Dai H, Xu S, Han J, Li Z, Cao J, Hu T, Li H, Wei J, Dou X, Zhou F*, Zheng J*: Prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy: a cross-sectional study. Journal of Affective Disorders 2021, 286:33-39.

9. Chen X, Li Z, Yong H, Wang W, Wang D, Chu S, Li M, Hou P, Zheng J*, Bai J*: Trim21-mediated HIF-1α degradation attenuates aerobic glycolysis to inhibit renal cancer tumorigenesis and metastasis. Cancer Letters 2021, 508:115-126.

10. Chai D, Zhang Z, Jiang N, Ding J, Qiu D, Shi SY, Wang G, Fang L, Li H, Tian H, Yang J, Zhang Q, Zheng J*: Co-munization with L-Myc enhances CD8+ or CD103+ DCs mediated tumor-specific multi-functional CD8+ T cell responses. Cancer Science 2021, 112(9):3469.

11. Zhang W, Zhang C, Tian W, Qin J, Chen J, Zhang Q, Fang L*, Zheng J*: Efficacy of an Oncolytic Adenovirus Driven by a Chimeric Promoter and Armed with Decorin Against Renal Cell Carcinoma. Hum Gene Ther 2020, 31(11-12):651-663.

12. Wang Y, Liu Y, Tan X, Pan B, Ge J, Qi K, Cheng H, Cao J, Shi M, Yan Z, Qiao J, Jing G, Wang X, Sang W, Xia R, Zhang X, Li Z, Gale RP, Zheng J*, Zhu F*, Xu K*: Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection. Leukemia 2020, 34(10):2704-2707.

13. Li Z, Wang D, Lu J, Huang B, Wang Y, Dong M, Fan D, Li H, Gao Y, Hou P, Li M, Liu H, Pan ZQ, Zheng J*, Bai J*: Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis. Cell Death Differ 2020, 27(12):3226-3242.

14. Lei M, Zheng G, Ning Q, Zheng J*, Dong D*: Translation and functional roles of circular RNAs in human cancer. Mol Cancer 2020, 19(1):30.

15. Duan Q, Zhang H, Zheng J*, Zhang L*: Turning cold into hot: firing up the tumor microenvironment. Trends in cancer 2020, 6(7):605-618.

16. Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, Shi M, Lan J, Fei X, Jin L, Jing G, Sang W, Zhu F, Chen W, Wu Q, Yao Y, Wang G, Zhao J, Zheng J*, Li Z*, Xu K*: A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol 2019, 6(10):e521-e529.

17. Guo Z, Wang G, Lv Y, Wan YY*, Zheng J*: Inhibition of Cdk8/Cdk19 Activity Promotes Treg Cell Differentiation and Suppresses Autoimmune Diseases. Front Immunol 2019, 10:1988.

18. Chai D, Shan H, Wang G, Zhang Q, Li H, Fang L, Song J, Liu N, Zhang Q, Yao H, Zheng J*: Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8(+) T-cell Responses. Mol Cancer Ther 2019, 18(2):323-334.

19. Cao J, Cheng H, Shi M, Wang G, Chen W, Qi K, Li H, Qiao J, Zhao J, Wu Q, Zeng L, Jing G, Zheng J*, Xu K*: Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia. Leukemia 2019, 33(11):2751-2753.

20. Bai J, Wu K, Cao M, Yang Y, Pan Y, Liu H, He Y, Itahana Y, Huang L, Zheng J*, Pan ZQ*: SCF(FBXO22) targets HDM2 for degradation and modulates breast cancer cell invasion and metastasis. Proc Natl Acad Sci U S A 2019, 116(24):11754-11763.

21. Wu B, Zhang S, Guo Z, Wang G, Zhang G, Xie L, Lou J, Chen X, Wu D, Bergmeier W, Zheng J*, Wan YY*: RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. Immunity 2018, 49(5):886-898 e885.

22. Hou P, Li L, Chen F, Chen Y, Liu H, Li J, Bai J*, Zheng J*: PTBP3-mediated regulation of ZEB1 mRNA stability promotes epithelial–mesenchymal transition in breast cancer. Cancer research 2018, 78(2):387-398.

23. Cao J, Wang G, Cheng H, Wei C, Qi K, Sang W, Zhenyu L, Shi M, Li H, Qiao J, Pan B, Zhao J, Wu Q, Zeng L, Niu M, Jing G, Zheng J*, Xu K*. Potent anti-mia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia. American journal of hematology 2018, 93(7):851-858.

24. Bai J, Yong H, Chen F, Mei P, Liu H, Li C, Pan Z, Wu Y, Zheng J*:Cullin1 is a novel marker of poor prognosis and a potential therapeutic target in human breast cancer. Annals of oncology 2013, 24(8):2016-2022.